Industry sources said Monday that South Korean pharmaceutical companies will start selling generic versions of Pfizer's smoking cessation drug Champix (varenicline tartrate), following the local expiration of its patent, as reported The Korea Bizwire.
Local companies, such as Hanmi Pharm and Jeil Pharmaceutical, have developed their own versions of the drug in anticipation of the patent expiration that occurred on July 19.
Hanmi already said it will officially supply its generic called Nocotin S on Monday with Jeil expected to follow suit with its own drug called Nico Chams.
Sales of Champix in South Korea rose tenfold to KRW 65 billion ($54 million) in 2017 from KRW 6.3 billion in 2014.
However, the numbers dropped to KRW 23.8 billion in 2019 with the popularity of e-cigarettes in the country.
To read more NewsPoints articles, click here.